Clinical trial
A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
NCT03425539 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 21, 2018
- Completion date
- September 2, 2021
- Enrollment
- 118 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.